Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 2,500
- Avg volume
- —
- Day's range
- $0.37 – $0.37
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was i...
Show more
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 81 3 5472 1125
- Website
- https://www.symbiopharma.com
- Address
- Toranomon Towers Office, 7th floor, 4-1-28 Toranomon, Minato, Japan
Latest news
No headlines yet.
